Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes

Gyre Therapeutics

07/08/2026 12:13

Overview
US-China biopharma firm's Q2 revenue fell yr/yr but beat analyst expectations
Company reported Q2 GAAP net loss widened, driven by higher R&D and transaction costs
Full-year 2026 revenue guidance of $100.5-$111.0 mln affirmed

Outlook
Gyre Therapeutics affirms full-year 2026 revenue guidance of $100.5 mln to $111.0 mln

Result Drivers
ETUARY SALES - Higher ETUARY sales volumes driven by focused marketing efforts, per company
COLLABORATION REVENUE LOSS - $3 mln decrease in collaboration revenue after Astellas agreement ended in March 2026
R&D AND TRANSACTION COSTS - Higher R&D expenses and Cullgen acquisition costs drove wider net loss

Company press release: ID:nGNX1M3Kfs

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$29.11 mln
$26.49 mln (3 Analysts)
Q2 Net Loss
 
$14.27 mln
 
Q2 Pretax Loss
 
$14.43 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Gyre Therapeutics, Inc. is $18.00, about 181.2% above its August 6 closing price of $6.40

Reuters Recommended Reads
Aug 6 - Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Aug 6 - Zentalis Q2 net loss widens on higher R&D costs
Aug 6 - CytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaboration

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)